Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935538 | 0.77 | ALDH1A1 (0.37) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL12411240 | 0.77 | FAAH (0.41) | ALDH1A1TSHRGLAKMT2ALMNA | |
| SCHEMBL14313870 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL273919 | 0.68 | KMT2A (0.46) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL20059312 | 0.68 | NPSR1 (0.38) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL10357566 | 0.68 | CTDSP1 (0.50) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL3257322 | 0.67 | NPSR1 (0.44) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL8060946 | 0.67 | NPSR1 (0.40) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL2390372 | 0.66 | NPSR1 (0.43) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL10874603 | 0.66 | NPSR1 (0.39) | ALDH1A1TSHRGLAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | ALDH1A1 4640/4885TSHR 3658/4885GLA 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.